The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17. by Meling, G. I. et al.
Br. J. Cancer (1993), 67, 88 92
© Macmillan Press
The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic
alterations on chromosome 17
G.I. Meling', R.A. Lothe3, A.-L. B0rresen3, C. Grauel, S. Haugel, O.P.F. Clausen2 &
T.O. Rognuml
'Institute ofForensic Medicine and 2lnstitute ofPathology, The National Hospital, University ofOslo; 3Department ofGenetics,
Institutefor Cancer Research, The Norwegian Radium Hospital, Oslo, Norway.
Summary In 231 colorectal carcinomas, allele variation at four restriction fragments length polymorphisms
(RFLP) loci on chromosome 17 have been studied by Southern analysis. Heterozygous loss of the TP53 gene
was found in 68% (129/189) of the carcinomas informative on both chromosome arms. In 41% (77/189) of the
carcinomas the loss was found only on 17p. Two probes were used to detect alterations on 17p, pBHP53 and
pYNZ22. When loss was demonstrated with pYNZ22, pBHP53 also always showed loss (n = 45), whereas
when loss was demonstrated with pBHP53, only 45 of 54 (83%) showed loss with pYNZ22. Loss on 17q was
found in 34% (64/189) of the carcinomas, and 6% (12/189) had loss on this chromosome arm, only. Loss on
17q was significantly associated with loss on 17p (P <0.01). These data confirm that the TP53 gene is the
target of loss on chromosome arm 17p in colorectal carcinomas, and demonstrate that loss of the TP53 gene is
most frequently part of limited, subchromosomal loss. Furthermore, the results do not suggest any additional
tumour suppressor gene(s) on chromosome 17 involved in colorectal carcinogenesis.
The role of loss of DNA sequences in carcinogenesis is a
matter of considerable interest, especially since such allele
loss may indicate the presence of a target suppressor gene
within the lost region (Knudson, 1985). A high frequency of
loss on chromosome arm 17p has been reported in colorectal
carcinomas (Fearon et al., 1987; Lothe et al., 1988; Vogel-
stein et al., 1988; Delattre et al., 1989; Baker et al., 1989),
and one target of this loss has been shown to be the TP53
gene (for review, Levine et al., 1991). Furthermore, most of
the colorectal carcinomas with loss of one TP53 gene allele
have revealed TP53 point mutations on the remaining allele
(Baker et al., 1989, 1990; Nigro et al., 1989), resulting in a
functionally inactive TP53 gene. However, the chromosomal
extent of the loss comprising the TP53 gene locus, and
thereby the relevance of loss detected on chromosome arm
17p as a reflection of changes of the TP53 gene, is not
similarly well characterised.
Allele amplification in colorectal carcinomas has so far not
been extensively studied by Southern analysis. The reason
might be that this genetic alteration is less frequently
observed than loss of heterozygosity, and because the con-
cept of tumour suppressor genes implies loss rather than gain
of DNA sequences. We have recently demonstrated allele
amplification within the Rb gene in 30% of colorectal car-
cinomas (Meling et al., 1991), suggesting a role also for
amplified genes in carcinogenesis in the colorectum.
The aim of this study was to analyse the frequency of loss
of the TP53 gene in a large series of colorectal carcinomas,
and to evaluate whether loss of this gene was part of local, or
whole chromosome loss. We have also studied the carcinomas
with regard to allele loss and allele amplification at other loci
on chromosome 17.
Materials and methods
Patients and tumour samples
Fresh tissue samples from 231 patients with colorectal
adenocarcinomas removed during laparotomy, were studied.
Six patients had more than one carcinoma synchronously,
and from these patients, only one tumour was studied to
exclude bias from mutual dependence of synchronous
tumours. The 119 male patients had a mean age of 68 years
(range 26 to 94 years), and the 112 female patients had a
mean age of 69 years (range 24 to 92 years). Dukes' stage
and tumour site are given in Table I.
Cell suspensions were mechanically prepared by mincing
tumour samples in phosphate-buffered saline (PBS) followed
by nylon mesh filtration (mesh pore size 70tm) (Seiden-
gazefabrik AG Thal, Switzerland). The cells were both fixed
and stored in 70% ethanol at 4°C, until DNA extraction was
performed. The degree of contamination of normal cells in
the tumour cell suspensions has recently been estimated by
cytological examination of cytospin preparations (Meling et
al., 1991). The cell suspensions contained a mean of 84%
tumour cells, ranging from 62% to 97%.
Southern analysis
Nuclear DNA was extracted from tumour cells and from
peripheral blood leucocytes in a 340A Nucleic Extractor
(Applied Biosystem, Rotterdam, Netherlands), principally
using standard methods (phenol-chloroform extraction and
ethanol precipitation) (Kunckel et al., 1977). DNA samples
(7.5pg) were digested to completion with approximately
eight times excess of the restriction enzymes BamHI, TaqI,
Table I Clinicopathological characteristics of the 231 colorectal
carcinomas studied
Clinicopathological
characteristics % (no. of tumours)
Dukes' stagea A 14% (33)
B 43% (99)
C 30% (68)
D 13% (31)
Tumour siteb
Right colon 31% (72)
Left colon 25% (57)
Rectum 44% (102)
aAccording to the modified Dukes' classification (Dukes, 1932;
Turnbull et al., 1967). bCarcinomas in the colon localised proximal
and distal to the mid-transverse colon, are classified as right- and
left-sided, respectively. Rectum is defined as the distal 15 cm of the
large bowel.
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and PvuII, respectively (Amersham, Buckinghamshire, Eng-
land). The DNA digests were separated in 1% agarose gels
(Sigma Chemical Co., St Louis, MO, USA) for 30 h at 48 V.
The DNA was transferred onto Nylon membranes (Bio-Rad,
Richmond, Ca, USA) according to a slightly modified
Southern procedure (Southern, 1975), using alkaline solution
(0.4 M NaOH and 0.6 M NaCl).
Hybridisation was performed using the probe pBHP53
(locus symbol TP53) which detects a BamHI-polymorphism
located on chromosome band 17p 13.1 and telomeric to the
TP53 gene (H0yheim et al., 1989, B. H0yheim, personal
communication, 1991). The probe pYNZ22 (D17S30), detec-
ting a VNTR polymorphism on 17p 13.3 (Nakamura et al.,
1988a), was hybridised to BamHI-digested DNA. The probe
pTHH59 (D17S4), detecting a VNTR polymorphism on
17q 23-q 25.3 (Nakamura et al., 1988b) was hybridised to
PvuII-digested DNA, and the probe pRMU3 (D17S24),
detecting a VNTR polymorphism on 17q 23-q 25.3 (Myers et
al., 1988, HGMII, 1991), was hybridised to TaqI-digested
DNA. Probe locations are shown in Figure 1.
The probes were radioactively labelled with [ax32P]dCTP
according to the random labelling method (Feinberg &
Vogelstein, 1983). Prehybridisations (2 h) and hybridisations
(overnight) were carried out in 0.5 M NaHPO4, pH 7.2,
0.001 M EDTA, 7% Sodium Dodecyl Sulfate (SDS), and 1%
Bovine Serum Albumin (BSA) at 65°C. After hybridisation,
the filters were washed for 10-15 min at 65°C in a 0.04 M
NaHPO4 solution, pH 7.2, containing 1% SDS. X-ray films
(Kodak, XAR-5, Eastman Kodak Company, Rochester, NY,
USA) were exposed to the radiolabelled filters for 1-7 days
at - 70°C using inteusifying screens (Kodak) before develop-
ment.
To evaluate the degree of intratumour variation, two to
five tissue samples from each of ten randomly chosen car-
cinomas were analysed for DNA alterations using the same
four probes.
Densitometric measurements and scoring criteria
Densitometric measurements were performed using a Bio-
Rad 1650 scanning densitometer on all the autoradiograms
of the heterozygous cases that had a visual allele imbalance
in hybridisation intensity compared with the normal alleles.
The membranes were rehybridised with an additional probe
to adjust for DNA loading. For this purpose, the probes
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Figure 1 Locations of the probes used on chromosome 17.
pYNZ2 hybridising to chromosome arm Ip (Nakamura et
al., 1988c), and pYNH24 hybridising to chromosome arm 2p
(Nakamura et al., 1987) were applied. Allele loss was defined
as a reduction of 33% or more in hybridisation intensity
(Chen et al., 1991, Meling et al., 1991), compared with the
intensity ofthe normal allele. Allele amplification was defined
as a 50% or more increase in hybridisation intensity (Meling
et al., 1991).
Statistical analysis
Differences in distributions were calculated by the chi-square
test with Yates' correction. P-values less than 0.05 were
considered to denote statistically significant differences.
Results
RFLP analysis
One hundred and eighty-nine cases (189/231 = 82%) were
heterozygous (informative) for polymorphism on both arms
of chromosome 17, i.e. for at least one locus on each
chromosome arm. In the following, the results are given as
number of cases in relation to the total of these 189 infor-
mative cases (if not otherwise specified). The number of
informative cases detected with each of the four probes, and
the frequencies of allele alterations detected, are given in
Table II. The allele changes observed are shown in Figure 2.
Allele alterations at 17p loci
Loss on chromosome arm 17p was demonstrated in 68% of
the tumours (129 cases), and amplification in 8% (15 cases)
(Table III). Amplification on 17p was always seen in com-
bination with loss on the other 17p arm (for the association
between loss on 17p and amplification on the other 17p arm,
P <0.01, Table IV). Significantly more tumours had loss
restricted to 17p (41%, 77 cases), than loss on both 17p and
17q (28%, 52 cases) (P <0.001) (Table III).
Of the total number of carcinomas analysed, 79 cases were
informative with both probes used on chromosome arm 17p.
When loss was demonstrated with pYNZ2, pBHP53 also
always showed loss (n = 45), whereas when loss was demon-
strated with pBHP53, only 45 of 54 (83%) showed loss with
pYNZ22 (for the association between loss at these two loci,
P <0.0001).
In the tumours with amplification on 17p, the mean in-
crease in hybridisation intensity found at the two loci on 17p
was 160% (range 50% to 300%).
Allele alterations at 17q loci
Loss on chromosome arm 17q was demonstrated in 34% of
the tumours (64 cases), amplification in 15% (29 cases)
(Table III), and both loss and amplification in 6% of the
tumours (12 cases). No association was found between loss
on 17q and amplification on the other 17q arm (Table IV).
Significantly more tumours had loss on both 17q and 17p
(28%, 52 cases) than loss restricted to 17q (6%, 12 cases)
(P <0.0001).
Of the total number of carcinomas analysed, 115 cases
were informative with both probes used on chromosome arm
Table II Frequencies of genetic alterations found in the 231
colorectal carcinomas
Percentages (proportions)
of informative cases with
Heterozygous Allele
Probe loss amplification Total
pBHP53 71% (70/99) 4% (4/99) 71% (70/99)
pYNZ22 61% (115/187) 9% (16/187) 61% (115/187)
pTHH59 23% (35/151) 11% (17/151) 29% (44/151)
pRMU3 33% (58/174) 13% (23/174) 41% (72/174)90 G.I. MELING et al.
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Figure 2 Allele changes detected on chromosome arm 17p by the probe pBHP53 on BamHI blots a, and on chromosome arm 17q
by the probe pTHH59 on Pvull blots b. DNA from normal (N) and tumour (T) tissue of three a and four b constitutionally
heterozygote patients, respectively, are shown. Rehybridisation with the probes pYNH24 a and pYNZ2 b were performed to adjust
for the amount of DNA loaded. Patients C912 and C1351 have no detectable change in the tumour. Patient C1339 and C1265 have
lost one allele. Patients C1151 and C1292 have amplification of one allele, and loss of the other allele. Patient C1170 has an
amplification of one allele. All patients with amplification of one allele as detected with pBHP53, had also loss of the other allele.
17q. Amplification on 17q was detected with only one of two
informative probes in 11% cases (13/115), and with both
probes in 6% cases (7/115).
In the tumours with amplification on 17q, the mean in-
crease in hybridisation intensity found at the two loci on 17q
was 90% (range 50% to 190%).
Inter-relation among alterations on chromosome 17
A significant association was found between loss on 17p and
loss on 17q P<0.01 (Table II). Amplification on 17p was
Table III Percentages (number) of tumours with allele alterations
among the 189 colorectal carcinomas informative on both
chromosome 17 arms
Alteration Chromosome arm % (no.) of tumours
Loss on 17 (either arm) 75% (141)
17p 68% (129)
17q 34% (64)
both 17p and 17q 28% (52)
Loss restricted to 17p 41% (77)
17q 6% (12)
Amplification 17p 8% (15)
17q 15% (29)
No chromosome 17 alteration 24% (45)
significantly less frequent than amplification on 17q P <0.05
(Table III). Amplification on 17q was not significantly associ-
ated with loss on 17p (Table IV). At the level of the two
individual loci on 17q, amplification of one allele was
associated with loss of the other allele at the locus detected
with pTHH59 (P <0.05), but not at the locus detected with
pRMU 3 (data not shown).
Intratumoural homogeneity
In seven of ten carcinomas, no intratumoural variation was
found, and in three carcinomas, a difference was found at
one of the four loci analysed. In one carcinoma, loss was
detected by the probe pYNZ22 in four of five samples. In
this carcinoma, the two other informative probes showed loss
in all samples (indicating whole chromosome loss in all sam-
ples). In one carcinoma, the probe pRMU3 detected allele
amplification in both samples, but loss of the other allele in
only one of them. In one carcinoma, allele amplification was
detected with pRMU3 in one sample, whereas in the other
sample, the increase in hybridisation did not reach the cut-off
value of 50%.
Discussion
In this study of 231 colorectal carcinomas, loss was the most
frequent alteration found on chromosome arm 17p, and
Table IV Pairwise comparisons of allele changes found in the 189 tumours informative on both
chromosome 17 arms
on J7p on J7q on J7p
loss+ loss- P loss+ loss- P ampl + ampl- P
on 17q
loss + 52 12 <0.01
loss - 77 48
on 17p
ampl+ 15 0 <01 9 6 <05
ampl - 114 60 <0.01 55 119 <°-°S
on 17q
ampl + 21 8 ns 12 17 4 25 ns
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could be detected in 68% of the carcinomas. In the majority
of these carcinomas (41% of the total number of informative
cases), the loss was found only on this chromosome arm.
Studies of breast cancer have demonstrated an increase in the
frequency of allele loss on 17p with increasing distance from
the TP53 gene locus to the telomeric end of the chromosome
arm, suggesting the existence of a tumour suppressor gene on
the distal part of 17p (Coles et al., 1990; Sato et al., 1990;
Andersen et al., 1992). From the present study on colorectal
carcinomas, the frequency of loss, as detected with the probe
pYNZ22, was lower than the frequency of loss detected with
the probe pBHP53, although not significantly so. When both
these probes were informative, every loss detected with the
probe pYNZ22 was also detected with pBHP53. These find-
ings argue against tumour suppressor gene(s) located distal to
the TP53 gene on chromosome arm 17p involved in colorec-
tal carcinogenesis. Furthermore, these data clearly show that
loss detected by either of these probes can be regarded as loss
of the TP53 gene.
Thirty-four per cent of the carcinomas had loss on 17q.
Loss on 17q was strongly associated with loss of the TP53
gene, suggesting that loss on 17q is frequently part of a more
extensive deletion that also comprises the TP53 gene, most
likely a part of a whole chromosome loss. The tumours with
loss on 17q not involving the TP53 gene constituted 6% of
the tumours. This low frequency most likely reflects that loss
on 17q is unspecific in these tumours. However, we cannot
rule out that among the tumors not showing allele loss on
17q, there may be tumours having abnormalities at a more
proximal site of this chromosome arm.
In general, allele amplification may indicate a specific
genetic change contributing in the carcinogenesis, or a com-
pensatory mechanism as response to a specific event, as for
instance loss of chromosomal segments (Cavenee et al.,
1983). Fifteen per cent of the tumours studied had amplifi-
cation on 17q, and a net gain of DNA sequences on 17q was
seen in the majority ofthese tumours. A gain ofchromosome
arm 17q in tumours with loss on 17p has earlier been found
in colorectal carcinomas by cytogenetic analysis (Muleris et
al., 1985, 1988). In our study, the amplification on 17q was
neither associated with loss on 17p, nor with loss on the
other 17q arm. This is in contrast to a previous report using
Southern analysis, demonstrating that gain of one 17q allele
was always followed by loss of the other allele (Fearon et al.,
1987). Amplification on 17p, found in a small proportion of
the tumours (8%), always occurred in combination with loss
on the other 17p arm. This is in agreement with earlier
reports, demonstrating that monosomy is an unstable condi-
tion, and single chromosomes tends to be duplicated after
loss has occurred of the other homologue chromosome (Eves
et al., 1983; Cavenee et al., 1983). However, since
amplification on 17p was associated with loss on the
homologue chromosome arm, whereas amplification on 17q
was not, different chromosomal mechanisms associated with
monosomy of 17p and of 17q may be indicated. The rela-
tively high frequency of amplification on 17q addresses the
possibility that amplification on 17q is a specific and not just
a random chromosomal event in colorectal carcinomas. This
question, however, needs further clarification.
In summary, loss of the TP53 gene was found in the
majority of the colorectal carcinomas, and was most fre-
quently part of a limited, subchromosomal deletion, as
oppossed to being part of a whole chromosome loss. Fur-
thermore, we found no evidence for any additional tumour
suppressor gene on chromosome 17 involved in colorectal
carcinogenesis. We therefore conclude that loss of the TP53
gene, as detected by Southern analysis and the two probes on
17p applied, denotes specific loss of this gene, and further-
more, that this loss is of functional importance for the
tumours with this change. To analyse the implications of loss
of the TP53 gene in colorectal carcinogenesis, we have
studied the relationship between loss of the TP53 gene and
clinicopathological variables of established prognostic impor-
tance. This analysis is presented in article II (Meling et al.,
1992).
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